Krystal Biotech KRYS announced that the FDA has approved a label update of its marketed product, Vyjuvek (beremagene geperpavec-svdt), to include dystrophic epidermolysis bullosa ("DEB") patients from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback